Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
101.00
+8.80 (9.54%)
Apr 28, 2026, 1:30 PM CST
65.03%
Market Cap 143.50B
Revenue (ttm) 38.04M
Net Income (ttm) -284.11M
Shares Out 1.56B
EPS (ttm) -0.18
PE Ratio n/a
Forward PE 29.62
Dividend n/a
Ex-Dividend Date n/a
Volume 4,134,918
Average Volume 15,025,387
Open 93.50
Previous Close 92.20
Day's Range 92.90 - 101.00
52-Week Range 61.70 - 277.00
Beta 1.37
RSI 43.94
Earnings Date May 5, 2026

About TPE:6919

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Tai... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6919
Full Company Profile

Financial Performance

In 2025, TPE:6919's revenue was 38.04 million, a decrease of -14.40% compared to the previous year's 44.43 million. Losses were -351.92 million, -40.23% less than in 2024.

Financial Statements

News

There is no news available yet.